🏢 官网IRSRRKCodex · 实盘不做把握 9/10
北京时间·🕒 发布 20:00:00时区推断·⟳ 抓取 20:02:20回填·⚡ 决策 07-16 20:04:13·102.9 天前
Scholar Rock 将于 2026年8月6日披露二季度业绩并召开电话会
本次公告仅为业绩披露日期和电话会安排，不包含二季度业绩数据、指引变化、产品进展或融资等可交易增量。
📄 原文SRRK↗ 原文
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
Skip to main navigation Skip to primary navigation Skip to main content Skip to primary sidebar Skip to footer Scholar…
不做 Scholar Rock（SRRK.US）
仅为二季度业绩披露日期和电话会安排公告，没有业绩结果、指引、管线进展或可量化基本面增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-16 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次公告仅为业绩披露日期和电话会安排，不包含二季度业绩数据、指引变化、产品进展或融资等可交易增量。
主要风险
- 若8月6日实际业绩或管线更新超预期，应由新信号重新研判。
原文全文
展开原文 · 4,937 字
Skip to main navigation
Skip to primary navigation
Skip to main content
Skip to primary sidebar
Skip to footer
Scholar Rock, Inc.
Careers
Newsroom
Contact Us
Learn about our commitment to creating possibilities for those living with serious disease.
Patients & Families
Our Company
Meet Scholar Rock, a biopharmaceutical company committed to improving lives.
Our Company
Our Science
Discover how our breakthrough approach treats complex disease at its biological root.
Our Science
Our Pipeline
Investors & Media
Investors & Media
Press Releases
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
Investors and Media
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
Main content section
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
July 16, 2026
PDF Version
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 16, 2026--
Scholar Rock (NASDAQ: SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026 , before the financial markets open.
The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET . To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com .
To participate via telephone, please register in advance here . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call.
An archived replay of the webcast will be available on the Company’s website for approximately 90 days.
About Scholar Rock
Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com , including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260716882246/en/
Scholar Rock Contacts
Investors
Laura Ekas, Ph.D.
ir@scholarrock.com
917-439-0374
Media
Jeff Smith
682-401-8428
Molly MacLeod, Ph.D.
802-579-5995
media@scholarrock.com
Source: Scholar Rock
Footer
Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142
Phone: 857.259.3860
info@scholarrock.com
© 2026 All Rights Reserved
We are Scholar Rock.
A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.
Learn More About Our Pipeline
Patients & Families
Areas of Focus
Spinal Muscular Atrophy
Patient Stories
Clinical Trials
Resources
Expanded Access
Our Company
Our Company
Mission & Vision
Newsroom
Careers
Management Team
Board of Directors
Our Science
Our Science
Platform
Publications & Posters
Our Pipeline
Neuromuscular and Obesity
Spinal Muscular Atrophy
Immuno-Oncology
Cancer (solid tumors)
Fibrotic Diseases
Hematology
Anemia
Investors & Media
Press Releases
Archived Press Releases
Events & Presentations
Corporate Governance
Management Team
Board of Directors
Committee Composition
Financials & Filings
SEC Filings
Stock Information
Historical Stock Lookup
Investment Calculator
Analyst Coverage
Investor FAQs
Contact IR or Media
Careers
Newsroom
Contact Us
Skip to primary navigation
Skip to main content
Skip to primary sidebar
Skip to footer
Scholar Rock, Inc.
Careers
Newsroom
Contact Us
Learn about our commitment to creating possibilities for those living with serious disease.
Patients & Families
Our Company
Meet Scholar Rock, a biopharmaceutical company committed to improving lives.
Our Company
Our Science
Discover how our breakthrough approach treats complex disease at its biological root.
Our Science
Our Pipeline
Investors & Media
Investors & Media
Press Releases
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
Investors and Media
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
Main content section
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
July 16, 2026
PDF Version
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 16, 2026--
Scholar Rock (NASDAQ: SRRK) today announced that it will report second quarter 2026 financial results on Thursday, August 6, 2026 , before the financial markets open.
The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET . To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com .
To participate via telephone, please register in advance here . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call.
An archived replay of the webcast will be available on the Company’s website for approximately 90 days.
About Scholar Rock
Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com , including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website, X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260716882246/en/
Scholar Rock Contacts
Investors
Laura Ekas, Ph.D.
ir@scholarrock.com
917-439-0374
Media
Jeff Smith
682-401-8428
Molly MacLeod, Ph.D.
802-579-5995
media@scholarrock.com
Source: Scholar Rock
Footer
Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142
Phone: 857.259.3860
info@scholarrock.com
© 2026 All Rights Reserved
We are Scholar Rock.
A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.
Learn More About Our Pipeline
Patients & Families
Areas of Focus
Spinal Muscular Atrophy
Patient Stories
Clinical Trials
Resources
Expanded Access
Our Company
Our Company
Mission & Vision
Newsroom
Careers
Management Team
Board of Directors
Our Science
Our Science
Platform
Publications & Posters
Our Pipeline
Neuromuscular and Obesity
Spinal Muscular Atrophy
Immuno-Oncology
Cancer (solid tumors)
Fibrotic Diseases
Hematology
Anemia
Investors & Media
Press Releases
Archived Press Releases
Events & Presentations
Corporate Governance
Management Team
Board of Directors
Committee Composition
Financials & Filings
SEC Filings
Stock Information
Historical Stock Lookup
Investment Calculator
Analyst Coverage
Investor FAQs
Contact IR or Media
Careers
Newsroom
Contact Us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。